Keck School Faculty

Casey O'Connell, MD
Casey O'Connell, MD
Associate Professor of Clinical Medicine, Lawrence and Janice Kelly Chair in Hematology;Medical Director for Anticoagulation Services for LAC+USC;Director, Gehr Cures: Myeloid Malignancy Program of USC
Medicine
1441 Eastlake Ave. Health Sciences Campus Los Angeles
Dr. Casey O’Connell is an Associate Professor in the Jane Anne Nohl Division of Hematology at the Keck School of Medicine, University of Southern California (USC). She did her undergraduate work at Stanford University and completed her medical degree with distinction at the George Washington School of Medicine. She began her career as a clinical researcher at USC’s Norris Comprehensive Cancer Center in the area of cancer-related thrombosis by describing the clinical significance of incidental pulmonary embolism identified on routine cancer staging CT scans. Her original work in this area was published in the Journal of Clinical Oncology and brought this clinical entity to the attention of oncologists worldwide. Dr. O’Connell’s background in cancer-related thrombosis has generated a focused interest in Myeloproliferative Neoplasms (MPNs), which include Polycythemia Vera, Essential Thrombocytosis and Myelofibrosis. In addition to leading clinical treatment trials for patients with these malignancies, she pursues translational research seeking to discover how they induce arterial and venous thrombosis. The MPNs and Myelodysplastic syndrome (MDS) are malignant hematopoietic disorders with pleiotropic clinical manifestations. Dr. O’Connell is interested in optimizing the role of epigenetic therapy in these pre-leukemic conditions that can lead to acute myeloid leukemia.

As director of the new GEHR CURES Myeloid Malignancy Program, Dr. O’Connell is focused on optimizing therapies and on novel ways to intervene earlier to prevent progression of these disorders. Dr. O’Connell is proudest of her accolades for patient care in Southern California and for teaching at the Keck School of Medicine, where she is the Director of the Year II Hematology Course.

Keck School of Medicine: Master Teacher Distinction, 2013

LAC+USC Medical Center: Medical Staff Leadership Recognition Award, 2013

Keck School of Medicine : Outstanding Year I Teaching Award, 2012-2013

Keck School of Medicine: Best Year I System, 2011-2012

Keck School of Medicine : Outstanding Year I Teaching Award, 2008-2009

Division of Hematology, USC: Fellow Research Award, 2006-2007

Division of Hematology, USC: Fellow Teaching Award, 2004-2005

USC Department of Medicine: Senior Resident of the Year, 2003-2004

USC Department of Medicine: Brautbar Teaching Award, 2003-2004

Keck School of Medicine: Outstanding Resident Teaching Award, 2003

George Washington University Department of Medicine: Jorge C. Rios Award in Internal Medicine, 2001

: Laszlo M Tauber Scholarship, 1999

George Washington University School of Medicine: William Beaumont Medical Research Honor Society, 1998

Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series Clin Lymphoma Myeloma Leuk. 2018 Jun 28. . View in PubMed

Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor SGI-110 in Hepatocellular Carcinoma Hepatology. 2018 May 18. . View in PubMed

Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center Platelets. 2018 Mar 26; 1-5. . View in PubMed

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia Cancer. 2018 Jan 15; 124(2):325-334. . View in PubMed

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial Lancet Oncol. 2017 Oct; 18(10):1317-1326. . View in PubMed

Management of the Incidental Pulmonary Embolism AJR Am J Roentgenol. 2017 Mar; 208(3):485-488. . View in PubMed

Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome Acta Haematol. 2017; 138(3):129-137. . View in PubMed

Initiating a Standard Venous Thromboembolism Prophylaxis Order Set Designed to Improve Patient Outcomes at Los Angeles County+University of Southern California Am Surg. 2016 Oct; 82(10):1000-1004. . View in PubMed

Correction of refractory thrombocytopenia and anemia following withdrawal of extended release niacin Am J Hematol. 2016 Jul; 91(7):E318. . View in PubMed

Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy Ann Hematol. 2016 Apr; 95(5):733-8. . View in PubMed

Incidental venous thromboembolic events in cancer patients: what we know in 2016 Thromb Res. 2016 Apr; 140 Suppl 1:S18-20. . View in PubMed

Emerging treatment options for myelofibrosis: focus on pacritinib Onco Targets Ther. 2016; 9:2655-65. . View in PubMed

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study Lancet Oncol. 2015 Sep; 16(9):1099-1110. . View in PubMed

How I treat incidental pulmonary embolism Blood. 2015 Mar 19; 125(12):1877-82; quiz 2009. . View in PubMed

Incidentally found pulmonary embolism: what's the clinician to do? Hematology Am Soc Hematol Educ Program. 2015; 2015:197-201.. View in PubMed

Approach to the management of incidental venous thromboembolic events in patients with cancer J Natl Compr Canc Netw. 2014 Nov; 12(11):1557-60. . View in PubMed

Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature Hum Pathol. 2014 Nov; 45(11):2183-91. . View in PubMed

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia J Clin Oncol. 2014 Jun 20; 32(18):1919-26. . View in PubMed

Experience with pegylated interferon a-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients Haematologica. 2012 Oct; 97(10):1570-3. . View in PubMed

Unsuspected pulmonary embolism: impact on mortality among cancer patients Curr Opin Pulm Med. 2012 Sep; 18(5):406-9. . View in PubMed

Treating venous thromboembolism in patients with cancer Expert Rev Hematol. 2012 Apr; 5(2):201-9. . View in PubMed

Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism J Clin Oncol. 2011 Nov 01; 29(31):4208-9; author reply 4209-10. . View in PubMed

Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning J Thromb Haemost. 2011 Feb; 9(2):305-11. . View in PubMed

A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation Epigenetics. 2010 Nov-Dec; 5(8):750-7. . View in PubMed

Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond Expert Rev Hematol. 2008 Dec; 1(2):175-82. . View in PubMed

Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance J Clin Oncol. 2006 Oct 20; 24(30):4928-32. . View in PubMed

Managing anemia in HIV-positive women Womens Health (Lond). 2006 Jan; 2(1):159-65. . View in PubMed

Powered by SC CTSI
Go to Top